Clinical Trials for Kidney Cancer

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed/refractory clear cell RCC after standard therapy (ECOG 0–1) receive XmAb819, a bispecific T‑cell engager targeting ENPP3 on tumor cells and CD3 on T cells, administered with IV or SC priming/step‑up dosing. Excludes prior anti‑ENPP3/CD203c therapy, active CNS disease (unless treated/stable), and active autoimmune disease requiring systemic therapy.

ClinicalTrials.gov ID: NCT05433142

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1: dose escalation enrolls any advanced solid tumor lacking standard options; expansion enrolls histologically confirmed ccRCC. Treatments include the oral HIF-2α inhibitor casdatifan (AB521) as monotherapy or combined with cabozantinib or the anti–PD-1 antibody zimberelimab.

ClinicalTrials.gov ID: NCT05536141

A Phase I/II Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with Receptor Tyrosine Kinase Inhibitor Resistant Renal Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced RCC that has progressed on prior RTKI therapy (ECOG 0–2) receive bicalutamide 50 mg daily (androgen receptor antagonist) plus sunitinib 25–50 mg on a 2-weeks-on/1-week-off schedule. Single-arm study assessing safety and objective response, with exploratory androgen-signaling biomarkers (AR IHC, AR-related miRNAs, KLK2).

ClinicalTrials.gov ID: NCT06222593

Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with multiple myeloma, leukemia, or lymphoma and moderate to severe renal impairment (including dialysis) who are candidates for commercial CAR T therapy receive renal function–adjusted fludarabine/cyclophosphamide lymphodepletion prior to CAR T infusion. The study assesses safety/feasibility (CRS, ICANS, cytopenias) of dose-reduced fludarabine (20–50%) and cyclophosphamide (0–25% reduction) based on renal function.

ClinicalTrials.gov ID: NCT05909059

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Untreated adults with stage IV clear cell–containing RCC (KPS ≥70%) are randomized to standard nivolumab plus ipilimumab versus a triplet adding relatlimab, a LAG‑3–blocking monoclonal antibody, to nivolumab and ipilimumab. Excludes prior systemic RCC therapy, CNS mets, and active autoimmune disease; endpoints include safety and antitumor activity (RECIST 1.1).

ClinicalTrials.gov ID: NCT06708949

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic non–clear cell RCC (papillary, chromophobe, oncocytic, unclassified/NOS; ≤1 prior systemic therapy) receive tivozanib (oral VEGFR-1/2/3 TKI) plus nivolumab (IV PD-1 inhibitor), including patients with controlled/asymptomatic brain metastases. Excludes prior tivozanib/nivolumab, medullary/collecting duct histologies, significant autoimmune disease, and uncontrolled hypertension.

ClinicalTrials.gov ID: NCT06053658

Phase 2, Open-label, Single Cohort, Multicenter Trial for Sequential Treatment of High Dose Cabozantinib on/After Progression on Cabozantinib Monotherapy in Advanced Renal Cell Carcinoma (Seq-Cabo)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable or metastatic RCC of any histology who previously benefited from and then progressed on cabozantinib 60 mg daily receive cabozantinib dose escalation to 80 mg daily. Cabozantinib is a multikinase inhibitor targeting VEGFR, MET, and AXL; prior PD-1/PD-L1 therapy is allowed, and participants must have measurable disease and ECOG 0–2.

ClinicalTrials.gov ID: NCT05931393

Phase II Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic renal cell carcinoma on a stable immune checkpoint inhibitor regimen who develop 1–5 oligoprogressive lesions receive SBRT to all progressing sites (with optional local therapies to some lesions) while continuing the same ICI. Excludes brain-only progression; aims to prolong disease control without switching systemic therapy.

ClinicalTrials.gov ID: NCT04974671

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors eligible for on-label PD-1 therapy (nivolumab or pembrolizumab) are randomized in a crossover design to receive standard PD-1 inhibitors via subcutaneous versus intravenous administration, assessing patient/clinician preference, satisfaction, QoL, safety, and selected clinical outcomes. Includes PD-(L)1–naïve patients or those willing to switch; excludes prior severe hypersensitivity and transplant history.

ClinicalTrials.gov ID: NCT07223424

PRISM: Phase 1b of Retifanlimab and Ruxolitinib In Solid Malignancies Progressing on Prior Checkpoint Inhibition

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced/metastatic clear cell renal cell carcinoma or non-small cell lung cancer who had at least stable disease on one prior line of PD-1/PD-L1 therapy but then radiographically progressed within 6 months of stopping it (ECOG 0–1; measurable disease; no active CNS disease or uncontrolled autoimmune disease) and lack/decline standard options. Patients receive retifanlimab (anti–PD-1 antibody) 500 mg IV every 4 weeks as checkpoint rechallenge combined with oral ruxolitinib (JAK1/2 inhibitor) twice daily with dose escalation to define the recommended dose.

ClinicalTrials.gov ID: NCT07219576